Multiple Myeloma | Specialty

Defining High-Risk Multiple Myeloma

January 12th 2016

Molecular Pathogenesis of Multiple Myeloma

January 12th 2016

Dr. Moreau on Tourmaline-MM1 Study for Multiple Myeloma

January 7th 2016

Philippe Moreau, MD, head of Department of Hematology, Centre Hospitalier et Universitaire, Nantes, France, discusses the phase III Tourmaline-MM1 study for patients with relapsed/refractory multiple myeloma.

Expert Discusses Promising Pembrolizumab Triplet in Advanced Myeloma

January 5th 2016

Jesus San Miguel, MD, PhD, discusses a phase I study examining pembrolizumab added to lenalidomide and low-dose dexamethasone in patients with heavily pretreated relapsed/refractory multiple myeloma, while emphasizing the need for further follow-up.

Dr. Hofmeister on Reolysin Combined With Carfilzomib for Multiple Myeloma

January 4th 2016

Craig Hofmeister, MD, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University, discusses a study that examined the efficacy of reolysin combined with carfilzomib in patients with relapsed multiple myeloma.

Clinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient–Upfront Transplant Versus Maintenance Therapy

December 31st 2015

With the development of novel therapies, the role and optimal timing of autologous stem cell transplant for the treatment of multiple myeloma have come into question.

Usmani on Personalized Combination Treatments for Myeloma Management

December 30th 2015

Saad Usmani, MD, discusses newly approved treatments for patients with multiple myeloma, as well as combination therapies currently being investigated in clinical trials.

Dr. Lonial on Novel Mechanisms in Multiple Myeloma

December 29th 2015

Sagar Lonial, MD, chief medical officer at Winship Cancer Institute of Emory University, discusses novel mechanisms of agents used for the treatment of patients with multiple myeloma.

Rajkumar on Triplet Regimens in Multiple Myeloma

December 22nd 2015

S. Vincent Rajkumar, MD, discusses a trial of bortezomib, lenalidomide, and dexamethasone versus lenalidomide plus dexamethasone in patients with previously untreated multiple myeloma.

HDACs Mark a Decade of Growth With New Solid Tumor Targets

December 16th 2015

Amid a growing understanding about the role of epigenetics as a driver of cancer, researchers have turned their attention to a key player in the process: histone deacetylases.

Dr. San Miguel on Pembrolizumab With Lenalidomide/ Dexamethasone in Multiple Myeloma

December 8th 2015

Jesus San Miguel, MD, PhD, professor of Hematology, medical director of the Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain, discusses the Keynote-023 study, which examined pembrolizumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.

Dr. Orlowski on Bortezomib Added to Lenalidomide and Dexamethasone for Multiple Myeloma

December 7th 2015

Robert Z. Orlowski, MD, PhD, Department Chair ad interim, Department of Lymphoma/Myeloma, Division of Cancer Medicine, professor, Florence Maude Thomas Cancer Research Professorship, The University of Texas MD Anderson Cancer Center, discusses the phase III SWOG 0777 study, which examined the addition of bortezomib to lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with previously untreated multiple myeloma.

Pembrolizumab Combo Generates High Response Rate in Refractory Myeloma

December 7th 2015

The addition of pembrolizumab to an established multiple myeloma regimen elicited responses in 76% of 17 patients with relapsed/refractory disease.

Daratumumab Combo Sparks 81% Response Rate in Myeloma

December 6th 2015

The addition of daratumumab to a standard multiple myeloma regimen generated responses in 81% of patients with relapsed or refractory disease that were "rapid, deep, and durable" without introducing any new safety concerns.

Dr. Kumar on Tourmaline-MM1 Study for Multiple Myeloma

December 6th 2015

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the phase III Tourmaline-MM1 study, which compared the efficacy of the addition of ixazomib to lenalidomide and dexamethasone with lenalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Oral Ixazomib Triplet Improves PFS in Myeloma

December 6th 2015

An all orally administered treatment regimen containing ixazomib, lenalidomide, and dexamethasone showed a 5.9-month improvement in progression-free survival compared with lenalidomide and dexamethasone alone for patients with relapsed/refractory multiple myeloma.

CAR T-Cell Infusion Leads to Eradication of Myeloma

December 5th 2015

Genetically engineered T cells eradicated multiple myeloma cells in a patient with advanced disease, suggesting the potential to cure the condition.

Ixazomib, Cyclophosphamide Combo Effective for Newly Diagnosed Myeloma

December 5th 2015

An all-oral triplet therapy of ixazomib, cyclophosphamide, and dexamethasone demonstrated promising early response rates in elderly patients with newly diagnosed multiple myeloma.

Durable Daratumumab Activity Highlighted in Combined Myeloma Analysis

December 5th 2015

Treatment with the CD38 monoclonal antibody daratumumab demonstrated a 31% overall response rate as monotherapy for patients with heavily pretreated multiple myeloma.

Dr. Young on Eltrombopag Added to Immunosuppression for Patients With Aplastic Anemia

December 5th 2015

Neal Young, MD, senior investigator, Cell Biology Section, National Heart, Lung, and Blood Institute, National Institute of Health, discusses a study that examined the efficacy of eltrombopag when added to standard immunosuppression for patients with aplastic anemia.